JPMorgan Chase & Co. Lowers Aptinyx (NASDAQ:APTX) to Underweight
A number of other research firms have also weighed in on APTX. Svb Leerink started coverage on shares of Aptinyx in a report on Thursday, June 20th. They issued an outperform rating and a $12.00 target price on the stock. Cowen restated a buy rating on shares of Aptinyx in a report on Monday, June 10th. Zacks Investment Research upgraded shares of Aptinyx from a hold rating to a buy rating and set a $4.25 target price on the stock in a report on Tuesday, July 16th. Cantor Fitzgerald restated a buy rating on shares of Aptinyx in a report on Tuesday, April 30th. Finally, ValuEngine upgraded shares of Aptinyx from a hold rating to a buy rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $12.71.
APTX opened at $3.27 on Tuesday. Aptinyx has a fifty-two week low of $2.88 and a fifty-two week high of $32.25. The company’s 50-day moving average is $3.62 and its 200 day moving average is $4.01.
Large investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co. NY increased its stake in Aptinyx by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 7,237 shares of the company’s stock valued at $120,000 after buying an additional 5,652 shares during the last quarter. Gabelli Funds LLC purchased a new stake in Aptinyx in the 1st quarter valued at about $44,000. Bank of America Corp DE increased its stake in Aptinyx by 430.0% in the 4th quarter. Bank of America Corp DE now owns 13,213 shares of the company’s stock valued at $218,000 after buying an additional 10,720 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Aptinyx during the 2nd quarter worth approximately $49,000. Finally, Millennium Management LLC purchased a new stake in shares of Aptinyx during the 4th quarter worth approximately $266,000. Hedge funds and other institutional investors own 58.30% of the company’s stock.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.